Invention Grant
US07790172B2 Methods for reducing nasopharyngeal colonization of non-typable Haemophilus influenzae with synthetic chimeric fimbrin peptides
失效
用合成嵌合Fimbrin肽减少非典型流感嗜血杆菌鼻咽定植的方法
- Patent Title: Methods for reducing nasopharyngeal colonization of non-typable Haemophilus influenzae with synthetic chimeric fimbrin peptides
- Patent Title (中): 用合成嵌合Fimbrin肽减少非典型流感嗜血杆菌鼻咽定植的方法
-
Application No.: US11745177Application Date: 2007-05-07
-
Publication No.: US07790172B2Publication Date: 2010-09-07
- Inventor: Lauren O. Bakaletz , Pravin T. P. Kaumaya
- Applicant: Lauren O. Bakaletz , Pravin T. P. Kaumaya
- Applicant Address: US OH Columbus
- Assignee: The Ohio State University
- Current Assignee: The Ohio State University
- Current Assignee Address: US OH Columbus
- Agency: Calfee, Halter and Griswold LLP
- Main IPC: A61K39/02
- IPC: A61K39/02

Abstract:
The present invention provides synthetic chimeric fimbrin peptides which induce an immunogenic response in animals to non-typable Haemophilus influenzae and that do not require tedious purification techniques. The synthetic chimeric fimbrin peptides reduce the severity of otitis media caused by Haemophilus influenzae. The synthetic chimeric fimbrin peptides are synthesized using commercially available peptide synthesizers. The synthetic chimeric fimbrin peptides comprises three peptide units. The first peptide unit is a subunit of the fimbrin protein. Preferably, the fimbrin subunit is comprised of the amino acids of Sequence ID No. 1 or Sequence ID No. 2. The second peptide unit is a t cell epitope, and preferably has the amino acid sequence of SEQ ID NO. 3. The third peptide unit is a linker peptide unit which joins the first and second peptide unit. The linking sequence preferably has from about 2 to about 15 amino acids, more preferably from about 2 to about 10 amino acids, most preferably from about 5 to about 6 amino acids. The synthetic chimeric fimbrin peptides are useful immunogens against NTHi and also useful as laboratory tool for detecting antibodies in sera. The invention also relates to an immunogenic composition containing the synthetic chimeric fimbrin peptides and a pharmacologically acceptable carrier.
Public/Granted literature
- US20070243206A1 SYNTHETIC CHIMERIC FIMBRIN PEPTIDES Public/Granted day:2007-10-18
Information query